RxDoctor Payments Data

Manny Silis, MD

Internal Medicine · Alexandria, VANPI 1407932635

Payments from drug & device makers

$8,018in general payments, 2019–2025

Across 405 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AstraZeneca$1K
  • Novo Nordisk$637
  • Amgen$517
  • Merck$504
  • Lilly USA, LLC$482
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$7,984100%
  • Entertainment$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,018 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$160,470
Medicare patients
337
Services billed
1,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$70,626
OzempicSemaglutide43$53,512
TrulicityDulaglutide33$30,366
JanuviaSitagliptin Phosphate32$29,397
JardianceEmpagliflozin42$28,356
LinzessLinaclotide14$12,116
MyrbetriqMirabegron47$11,229
Divalproex Sodium50$10,196
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$7,941
XareltoRivaroxaban15$7,601
Breo ElliptaFluticasone/Vilanterol16$7,472
Felbamate14$5,016
TrintellixVortioxetine Hydrobromide20$4,897
Atorvastatin Calcium299$4,243
Pantoprazole Sodium164$3,820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,170$70,626158 claims
Novo NordiskOzempic$637$53,51243 claims
Lilly USA, LLCTrulicity$482$30,36633 claims
MerckJanuvia$504$29,39732 claims
Boehringer IngelheimJardiance$110$28,35642 claims
AbbVieLinzess$422$12,11614 claims
Astellas Pharma US IncMyrbetriq$199$11,22947 claims
Johnson & JohnsonXarelto$258$7,60115 claims
GSKBreo Ellipta$257$7,47216 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$43$4,89720 claims
Kowa Pharmaceuticals America, Inc.Livalo$94$3,64012 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$170$1,80384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →